The testing of an IDO-silenced DC vaccine in a small cohort of patients with ovarian and uterine cancer demonstrated that DCs upregulate CD40, CCR7 and may enhance their immunogenic functions in the absence of IDO while CD80 and CD86 do not appear affected [350]. Here, IDO1 is linked to uterine cancer.